Cargando…
A unique peptide deformylase platform to rationally design and challenge novel active compounds
Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071857/ https://www.ncbi.nlm.nih.gov/pubmed/27762275 http://dx.doi.org/10.1038/srep35429 |
_version_ | 1782461339017412608 |
---|---|
author | Fieulaine, Sonia Alves de Sousa, Rodolphe Maigre, Laure Hamiche, Karim Alimi, Mickael Bolla, Jean-Michel Taleb, Abbass Denis, Alexis Pagès, Jean-Marie Artaud, Isabelle Meinnel, Thierry Giglione, Carmela |
author_facet | Fieulaine, Sonia Alves de Sousa, Rodolphe Maigre, Laure Hamiche, Karim Alimi, Mickael Bolla, Jean-Michel Taleb, Abbass Denis, Alexis Pagès, Jean-Marie Artaud, Isabelle Meinnel, Thierry Giglione, Carmela |
author_sort | Fieulaine, Sonia |
collection | PubMed |
description | Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed to get complete sets of 3-dimensional, biophysical and kinetic data with virtually any inhibitor compound. Structure-activity relationship analysis with this single reference system allowed us to reveal distinct binding modes for different PDF inhibitors and the key role of a hydrogen bond in potentiating the interaction between ligand and target. We propose this protein as an irreplaceable tool, allowing easy and relevant fine comparisons between series, to design, challenge and validate novel series of inhibitors. As proof-of-concept, we report here the design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug resistant clinical isolate. |
format | Online Article Text |
id | pubmed-5071857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50718572016-10-26 A unique peptide deformylase platform to rationally design and challenge novel active compounds Fieulaine, Sonia Alves de Sousa, Rodolphe Maigre, Laure Hamiche, Karim Alimi, Mickael Bolla, Jean-Michel Taleb, Abbass Denis, Alexis Pagès, Jean-Marie Artaud, Isabelle Meinnel, Thierry Giglione, Carmela Sci Rep Article Peptide deformylase (PDF) is considered an excellent target to develop antibiotics. We have performed an extensive characterization of a new PDF from the pathogen Streptococcus agalactiae, showing properties similar to other known PDFs. S. agalactiae PDF could be used as PDF prototype as it allowed to get complete sets of 3-dimensional, biophysical and kinetic data with virtually any inhibitor compound. Structure-activity relationship analysis with this single reference system allowed us to reveal distinct binding modes for different PDF inhibitors and the key role of a hydrogen bond in potentiating the interaction between ligand and target. We propose this protein as an irreplaceable tool, allowing easy and relevant fine comparisons between series, to design, challenge and validate novel series of inhibitors. As proof-of-concept, we report here the design and synthesis of effective specific bacterial PDF inhibitors of an oxadiazole series with potent antimicrobial activity against a multidrug resistant clinical isolate. Nature Publishing Group 2016-10-20 /pmc/articles/PMC5071857/ /pubmed/27762275 http://dx.doi.org/10.1038/srep35429 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Fieulaine, Sonia Alves de Sousa, Rodolphe Maigre, Laure Hamiche, Karim Alimi, Mickael Bolla, Jean-Michel Taleb, Abbass Denis, Alexis Pagès, Jean-Marie Artaud, Isabelle Meinnel, Thierry Giglione, Carmela A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title | A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title_full | A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title_fullStr | A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title_full_unstemmed | A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title_short | A unique peptide deformylase platform to rationally design and challenge novel active compounds |
title_sort | unique peptide deformylase platform to rationally design and challenge novel active compounds |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071857/ https://www.ncbi.nlm.nih.gov/pubmed/27762275 http://dx.doi.org/10.1038/srep35429 |
work_keys_str_mv | AT fieulainesonia auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT alvesdesousarodolphe auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT maigrelaure auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT hamichekarim auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT alimimickael auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT bollajeanmichel auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT talebabbass auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT denisalexis auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT pagesjeanmarie auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT artaudisabelle auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT meinnelthierry auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT giglionecarmela auniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT fieulainesonia uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT alvesdesousarodolphe uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT maigrelaure uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT hamichekarim uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT alimimickael uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT bollajeanmichel uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT talebabbass uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT denisalexis uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT pagesjeanmarie uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT artaudisabelle uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT meinnelthierry uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds AT giglionecarmela uniquepeptidedeformylaseplatformtorationallydesignandchallengenovelactivecompounds |